<p>MIC distribution of fosfomycin for <i>Campylobacter jejuni</i> and <i>C</i>. <i>coli</i> isolates from different sources.</p
<p>MICs of tylosin, tilmicosin, spectinomycin, oxytetracycline and florfenicol for 27 <i>M. bovis</i...
<p>MIC reduction assay of isolates that demonstrated synergy between CCCP and one of the tested anti...
<p>MP, meropenem; IP, imipenem; RI, rifampicin; AB, ampicillin+sulbactam; TCG, tigecycline; CO, coli...
MIC distribution for antibiotics (CFDC, MEM, CAZ, CPM and COL) tested on the bacterial strains.</p
<p>MIC distribution of 500 <i>E. coli</i> isolates (in %) tested for their antimicrobial susceptibil...
<p>Distribution of <i>Campylobacter</i> isolates with CGF data by year and by origin available for s...
<p>Distribution of infectious foci in different groups of bacterial etiology.</p
<p>Characterization of fosfomycin-resistant <i>Campylobacter</i> strains in this study.</p
<p>Distribution of MICs according to the phylum of clinical isolates and reference strains.</p
Fosfomycin is re-evaluated as a treatment of multidrug-resistant Enterobacteriaceae infections. Howe...
<p>MICs of antimicrobial agents for <i>E</i>. <i>coli</i> clinical isolates from Myanmar.</p
Clonal relationship between Escherichia coli isolates from different sources.</p
Distribution of E. coli and ciprofloxacin resistant E. coli isolated from poultry, poultry farm envi...
<p><i>Campylobacter</i> isolates obtained from human cases and from the sampled animal reservoirs.</...
<p>Interrupted lines denote MIC breakpoints of the antimicrobials for susceptible (left line) and re...
<p>MICs of tylosin, tilmicosin, spectinomycin, oxytetracycline and florfenicol for 27 <i>M. bovis</i...
<p>MIC reduction assay of isolates that demonstrated synergy between CCCP and one of the tested anti...
<p>MP, meropenem; IP, imipenem; RI, rifampicin; AB, ampicillin+sulbactam; TCG, tigecycline; CO, coli...
MIC distribution for antibiotics (CFDC, MEM, CAZ, CPM and COL) tested on the bacterial strains.</p
<p>MIC distribution of 500 <i>E. coli</i> isolates (in %) tested for their antimicrobial susceptibil...
<p>Distribution of <i>Campylobacter</i> isolates with CGF data by year and by origin available for s...
<p>Distribution of infectious foci in different groups of bacterial etiology.</p
<p>Characterization of fosfomycin-resistant <i>Campylobacter</i> strains in this study.</p
<p>Distribution of MICs according to the phylum of clinical isolates and reference strains.</p
Fosfomycin is re-evaluated as a treatment of multidrug-resistant Enterobacteriaceae infections. Howe...
<p>MICs of antimicrobial agents for <i>E</i>. <i>coli</i> clinical isolates from Myanmar.</p
Clonal relationship between Escherichia coli isolates from different sources.</p
Distribution of E. coli and ciprofloxacin resistant E. coli isolated from poultry, poultry farm envi...
<p><i>Campylobacter</i> isolates obtained from human cases and from the sampled animal reservoirs.</...
<p>Interrupted lines denote MIC breakpoints of the antimicrobials for susceptible (left line) and re...
<p>MICs of tylosin, tilmicosin, spectinomycin, oxytetracycline and florfenicol for 27 <i>M. bovis</i...
<p>MIC reduction assay of isolates that demonstrated synergy between CCCP and one of the tested anti...
<p>MP, meropenem; IP, imipenem; RI, rifampicin; AB, ampicillin+sulbactam; TCG, tigecycline; CO, coli...
DOI
Add to ORKG